There are so many types of cancer out there, it’s easy for them to pass under the radar. For a disease where early detection is critical, getting the right test is extremely important.
Category: Treatment Updates
Protect our Access: Update on Changes to the Patent Medicines Pricing Review Board (PMPRB)
The federal government’s plan to push patented drug prices lower continues to meet with controversy. The changes to the regulations governing the Patented Medicine Prices Review Board (PMPRB) have aroused criticism from
Health technology assessment agency gives recommendation for OPDIVO to treat non-small cell lung cancer
OPDIVO™ is the first immuno-oncology therapy for lung cancer in Canada to use the body's own immune system to fight cancer MONTREAL, June 8, 2016 /CNW/ – Canada's national health technology assessment body (CADTH) today made
Positive Lung Cancer pCODR recommandation for Opdivo
Hot from the press, BMS just received the final pCODR recommendation for Opdivo in lung cancer. PERC has maintained its initial recommendation with no change. This is an excellent news for the patients.
New Cancer Immunotherapy Indication for Canadian Patients with Untreated Metastatic Melanoma
KIRKLAND, QC, May 31, 2016 /CNW Telbec/ – Merck (NYSE: MRK), known as MSD outside Canada and the United States, announced today that KEYTRUDA® (pembrolizumab) received approval for the treatment of patients with unresectable or metastatic melanoma who
Ask an Expert: Febrile Neutropenia Explained
Introduction: Febrile neutropenia, or FN, is a common and potentially serious side effect of chemotherapy treatment. Neutrophils are a type of white blood cell responsible for helping fight germs and infections. Neutropenia